Key facts
- This page summarizes Paul L. Berns's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Aug 2021, 18:37.
Paul L. Berns - 05 Aug 2021 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- Director
- Issuer ticker
- JAZZ
- Reported as of
- 05 Aug 2021
- Net transaction value
- -$223,300
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2021, 18:37:36 UTC
- Prior SEC filing
- 28 Jun 2021
- Next SEC filing
- 20 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Paul L Berns
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul L. Berns filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 09 Aug 2021.
Change
- Previous filing in this sequence was filed on 28 Jun 2021.
- Current net transaction value: -$223,300.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Sale
- Transaction value
- $223,300
- Shares
- -1,450
- Change %
- -15%
- Price
- $154.00
- Shares after
- 8,290
- Date
- 05 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Paul L. Berns is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.